Application No.: 10/053,753 Docket No.: 05031.0003.CNUS02

AMENDMENTS TO THE CLAIMS

- 1-64 (Previously cancelled)
- 65. (Currently amended) An antibody that specifically binds to a polypeptide comprising a sequence set forth in SEQ ID NO:4, wherein the antibody binds to a portion of the sequence set forth in SEQ ID NO:4 that is divergent from the sequence set forth in SEQ ID NO:2.
 - 66. (Previously cancelled)
- 67. (Currently amended) An antibody that specifically binds to a polypeptide comprising a fusion protein, said fusion protein comprising a sequence set forth in SEQ ID NO:4, wherein said antibody specifically binds to a portion of the sequence set forth in SEQ ID NO:4, and wherein the portion is divergent from the sequence set forth in SEQ ID NO:2.
- 68. (Previously presented) The antibody according to claim 65, wherein said antibody further comprises a label.
- 69. (Previously presented) The antibody according to claim 68, wherein said label is selected from the group consisting of an enzyme, protein, peptide, antigen, antibody, lectin, carbohydrate, biotin, avidin, radioisotope, toxin and heavy metal.
- 70. (Previously amended) The antibody according to any one of claims 65 or 67-69, wherein said antibody is a humanized antibody.
- 71. (Previously amended) The antibody according to any one of claims 65 or 67-69, wherein said antibody is a CDR-grafted antibody.
- 72. (Previously amended) The antibody according to any one of claims 65 or 67-69, wherein said antibody is a chimeric antibody.
- 73. (Previously amended) The antibody according to any one of claims 65 or 67-69, wherein said antibody is an antibody fragment.
- 74. (Previously amended) The antibody according to any one of claims 65 or 67-69, wherein said antibody is a monoclonal antibody.
- 75. (Previously amended) The antibody according to any one of claims 65 or 67-69, wherein said antibody is a polyclonal antibody.

Application No.: 10/053,753 Docket No.: 05031.0003.CNUS02

76. (Previously amended) A pharmaceutical composition comprising the antibody according to any one of claims 65 or 67-69, and a pharmaceutically acceptable adjuvant, diluent, or a carrier.

77. (Previously amended) A kit comprising the antibody according to any one of claims 65 or 67-69.

78-81 (Previously cancelled)